**Additional files**

Intravenous Pulse Methylprednisolone For Induction Of Remission In Severe ANCA Associated Vasculitis: A Multi-Center Retrospective Cohort Study

Dimitrios Chanouzas PhD1,2, JulieAnne G. McGregor MD3, Peter Nightingale PhD2, Alan D. Salama PhD4, Wladimir M. Szpirt MD5, Neil Basu PhD6, Matthew David Morgan PhD1,2, Caroline J. Poulton MSW3, Juliana Bordignon Draibe MD4, Elizabeth Krarup MD5, Paula Dospinescu MBChB6, Jessica Anne Dale MBChB2, William Franklin Pendergraft PhD3, Keegan Lee MBChB4, Martin Egfjord PhD5, Susan L. Hogan PhD3 and Lorraine Harper PhD1,2.

**Additional file Table S1**  Intravenous pulse methylprednisolone use and dosage

|  |  |  |
| --- | --- | --- |
|  | MP use | MP dose (g)\* |
| Birmingham | 9/23 | 1.00 (0.50-1.75) |
| Chapel Hill | 30/32 | 1.50 (1.50-2.19) |
| London | 9/10 | 1.50 (1.50-1.50) |
| Copenhagen | 3/36 | 1.50 (1.50-1.50) |
| Aberdeen | 1/13 | 3.00 (3.00-3.00) |

\* Median (IQR) in patients that received intravenous pulse methylprednisolone (MP)

**Additional file Table S2** Cyclophosphamide and oral prednisolone dose in intravenous pulse methylprednisolone (MP) and non-MP treated patients

|  |  |  |
| --- | --- | --- |
|  | MP | Non-MP |
| Cyclophosphamide (g) |  |  |
| 2 weeks | 1.0 (0.8 – 1.2) | 1.4 (0.8 – 1.5) |
| 1 month | 1.4 (1.0 – 1.8) | 2.7 (1.5 – 3.0) |
| 3 months | 4.5 (3.1 – 4.9) | 6.5 (4.5 – 9.0) |
| 6 months | 5.2 (3.6 – 9.4) | 8.6 (6.4 – 10.5) |
|  |  |  |
| Oral prednisolone (g) |  |  |
| 1 week | 0.4 (0.4 – 0.4) | 0.4 (0.4 – 0.4) |
| 2 weeks | 0.8 (0.8 – 0.8) | 0.8 (0.8 – 0.8) |
| 1 month | 1.8 (1.4 – 1.8) | 1.6 (1.4 – 1.7) |
| 3 months | 3.8 (2.9 – 3.8) | 3.9 (3.0 – 4.1) |
| 6 months | 4.0 (3.9 – 4.0) | 5.6 (4.4 – 6.3) |
| 12 months | 4.0 (3.9 – 5.3) | 6.8 (5.5 – 7.0) |

Median (IQR) shown

Cumulative dose up to the respective time point is shown





**Additional file Table S3** Factors associated with infection at 3 months on univariable and multivariable proportional hazards analysis

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Univariable | | Multivariable | |
|  | HR (95% CI) | p value | HR (95% CI) | p value |
| *(A) Time to infection at 3 months* |  |  |  |  |
| MP dose (per gram) | 1.4 (1.1 – 1.9) | 0.017 | 1.5 (1.1 – 1.9) | 0.010 |
| Leukopenia preceding infection | 3.6 (1.6 – 8.0) | 0.001 | 3.9 (1.8 – 8.6) | 0.001 |
| Dose of oral prednisolone, g | 5.4 (1.1 – 27.3) | 0.043 | 7.2 (1.2 – 44.7) | 0.035 |
|  |  |  |  |  |
| *(B) Time to severe infection at 3 months* |  |  |  |  |
| MP dose (per gram) | 1.5 (1.1 – 2.1) | 0.016 | 1.44 (1.03 – 2.00) | 0.034 |
| Leukopenia preceding infection | 4.8 (2.1 – 10.9) | < 0.001 | 5.35 (2.34 – 12.23) | < 0.001 |
| Dose of oral prednisolone, g | 9.2 (1.5 – 54.7) | 0.015 | 15.20 (1.71 – 134.99) | 0.015 |
| BVAS score | 1.1 (1.0 – 1.2) | 0.005 | 1.08 (0.97 – 1.20) | 0.169 |
| Lung involvement | 1.9 (0.9 – 3.9) | 0.096 | 0.93 (0.37 – 2.38) | 0.884 |

Dose of oral prednisolone was entered as a segmented time dependent variable as follows: dose at 1 week, 2 weeks, 1 month and 3 months.

HR = hazard ratio, CI = confidence intervals

The differences in infection and severe infection between MP treated patients and patients that did not receive MP were confined to the first 3 months. As shown in Additional file Figure S1, there is a clear difference in infection between the 2 groups at 3 months. There is no difference in the occurrence of new infections from 3 to 12 months between MP and non-MP treated patients.



A

B

C

D

**Additional file Figure S1** Time to infection by 3 months (A) and from 3 to 12 months (B) and time to severe infection by 3 months (C) and from 3 to 12 months (D) was examined by Kaplan-Meier curve analysis. Time for infection for patients that received MP is shown in the dashed line and that for non-MP treated patients in the solid line.